Core Scientific (CORZ) recently expanded its delayed draw bridge credit facility, increasing total term loan commitments to US$1.0b and drawing the full US$500.0m incremental tranche, a sizeable move for shareholders to consider.
See our latest analysis for Core Scientific.
The financing news lands at a time when Core Scientific's 1-day share price return of 6.08% and 30-day share price return of 6.08% suggest building momentum, while its 1-year total shareholder return of 126.99% points to a strong recent run overall.
If this type of move has you thinking about what else could be setting up in related areas, it could be worth scanning 20 cryptocurrency and blockchain stocks for other cryptocurrency and blockchain names catching market interest.
With Core Scientific now sitting at US$16.23 and analyst targets around US$26.40, plus rapid revenue and net income growth alongside a sizeable new loan, investors have to ask: is there real upside left here, or is the market already pricing in future growth?
Most Popular Narrative: 38.5% Undervalued
With Core Scientific closing at $16.23 against a narrative fair value of $26.40, the most followed view in the market is building in a sizeable gap between price and potential, centred on an aggressive shift toward high performance computing and AI hosting.
Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12-year term, significantly boosting future revenue compared to their current levels. The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise.
Curious how a single contract, a rapid pivot away from pure Bitcoin mining, and sharply higher margin assumptions come together to support that fair value gap? The full narrative lays out an aggressive revenue ramp, a profit profile that looks very different to today, and a valuation multiple usually reserved for mature software names.
Result: Fair Value of $26.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on Core Scientific both ramping AI and HPC capacity on schedule and managing its heavy reliance on CoreWeave for that projected revenue.
Find out about the key risks to this Core Scientific narrative.
Another Way To Look At Valuation
The narrative fair value suggests upside, but the current P/S of 16x is far above the US Software industry at 3.5x, the peer average at 12.5x, and even the fair ratio of 5.1x. That rich revenue multiple raises a simple question: how much optimism is already in the price?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With such a mixed picture on growth, contracts, and valuation, it makes sense to look at the underlying data yourself and move quickly to shape your own view, including how the company balances potential upside with the 1 key reward and 2 important warning signs
Looking for more investment ideas?
If Core Scientific has sharpened your focus, do not stop here; broaden your watchlist with other ideas that match the kind of portfolio you want to build.
- Target potential value opportunities by scanning 62 high quality undervalued stocks that pair stronger fundamentals with pricing that some investors may have overlooked.
- Strengthen your focus on resilience by checking 67 resilient stocks with low risk scores that score well on stability and lower overall risk profiles.
- Spot lesser known opportunities early by reviewing the screener containing 25 high quality undiscovered gems before they attract wider market attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com